Xiaofeng Li Email & Phone Number

Boston, Ma, Us

Paris, France, Fr

Cell Therapies/Analytical Development group • Led and contributed to diverse stages of cell therapy assay development and validation including: Characterization: Potency, Identity, and Purity Testing Product Safety: Microbial Testing (adventitious agents) Consistency: Specification, Stability, Comparability Testing Manufacturing: QC/QA tracking, Process Control• Serve as a subject matter expert in immunology, characterization of patient starting materials, and product. Designed and developed exploratory and extended characterization assays to evaluate cell lineage, receptor expression, cytokine secretion and intracellular production, cell proliferation, degranulation, and cytotoxicity.• Specialized in assay development (flow cytometry(FACSLyric)/Elisa/MSD), optimization, miniaturization, bridging, and transfer.• Authored SOPs, qualification experimental plan, qualification report, and actively contributed to regulatory and quality documentation.

Cambridge, Ma, Us

Cambridge, Ma, Us

• Served as the biology program lead in Alzheimer’s Disease (AD) Genetic Targets team• Contributed to multi-disciplinary project teams in a matrix organization and managed preclinical model development leveraging transgenic mouse and human cellular systems • Effectively communicated program progress and strategy to project and management teams • Experience leveraging diverse modalities approaches to target high-value human genetic hubs (SM/Antibody/siRNA) • Developed and applied chemical, lipid, cellular, immunoassay, and molecular techniques to establish human chain-of-translatability, advance drug discovery hypotheses, and programs• Contributed to two in-house ApoE phenotypic screens in human astrocyte model systems• Advanced lead program from HTS campaign, to Hit ID, Lead selection, and target deconvolution• Established in vitro (IPSC-astrocyte/microglia) & in vivo models to support phenotypic screen hit validation, enable PK/PD confidence, and efficacy studies to support Lead selection• Developed, optimized, and patented a novel quantitative assay of ApoE lipidation status validated in human iPSC ApoE genetic model systems and human CSF (one of three inventors)• Enabled precision biomarker strategy to complement patient genetic stratification• Awarded Scientific Rigor Award (2022) as recognition for key impact on Neurodegenerative Disease Research Unit• Managed and mentored scientists, research fellows, and contractors

Us

• Research focuses on the role of lipid mediators in the regulation of inflammation resolution. • Identified specific lipid mediators in fibrosis, infections, tissue repair, and regeneration via LC-MS-MS• Explored the function of selected novel lipid mediators by employing multiple molecular profiling approaches, notably gene expression arrays and immunoassay• Employed a broad range of human primary keratinocyte/endothelial cell functional assays to pheno-profile cellular metabolism, proliferation, migration, permeability, and apoptosis to analyze the novel mechanisms of lipid mediators.

Boston, Ma, Us

Miami, Fl, Us

• Described a novel mechanism for calcineurin Aβ catalytic subunit compartmentation by polyproline-dependent binding to CIP4 • Identified Cdc42-interacting protein (CIP4/TRIP10) as a key scaffold protein and modulatory hub for cardiac hypertrophy and heart failure• Employed proximity ligation and Co-IP approaches to support protein interaction in primary adult rat myocytes• Engineered a live-cell FRET virus vector (CIP4-Cameleon calcium sensor)• Optimized and applied CIP4 gene deletion and inhibition approaches of calcineurin Aβ polyproline-dependent anchoring to support in vitro to in vivo translation in mice

Phd Student, Atherosclerosis And Lipid Metabolism

Master'S Degree, Biochemistry And Molecular Biology

Bachelor'S Degree, Biological Technology